

1 **Washington Vaccine Association**
2 **Combined Operations and Vaccine Committee Meeting**
3 **via Teleconference**
4 **May 3, 2018; 12:00-1:00 p.m. PST**

5
6 **I. Attendance.** Participating in all or part of the meeting by telephone were the following
7 individuals:

Members

Michele Roberts, MPH, MCHES, Department of Health
Cathy Falanga, Aetna
John Dunn, MD, Kaiser Permanente
Jeffrey Gombosky
Chad Murphy, Premera

Absent

Ed Marcuse, MD, Chairman
Rachel Wood, MD
Lisa Johnson, MD
Jeffrey Duchin, MD

KidsVax[®]

Julia Zell, Executive Director-WVA
Peter Smith, CPA
Norm Roberge, Outside Analyst
Heather Veen, Sr. Executive Assistant/Paralegal
Stephanie Mudgett, Independent Contractor

Others

SheAnne Allen, MPH, MCHES, Department of Health
Anne Redman, Perkins Coie
Tawnya Flyberg, Premera
Julie Liu, AstraZeneca
Stephanie Crook, United Healthcare
Brandon Jensen, United Healthcare
Laura McKenna, Regence
Jeri Trice, Zenith

8 **II. Follow up Tasks/Action Items**

- 9 1. SheAnne Allen will make final corrections to the 2018 Assessment Grid regarding all flu
10 assessments.
11 2. Survey results from providers regarding FluMist will be reviewed, compiled, and distributed
12 prior to approval of 2018 Assessment Grid.
13 3. Ms. Zell to communicate with AstraZeneca to confirm return policy and cost, and use Dr.
14 Marcuse, Dr. Dunn, Ms. Allen, and Dr. Harvey as resources.

- 1 4. Ms. Zell to post and share provider and payer pages on WVA website, as well as final
2 assessment grid with changes.
3
4

5 **III. Minutes**

6 Welcome and Introductions

7 At 12:02 p.m., a quorum having been established via telephone for both the Operations and Vaccine
8 Committees, Ms. Zell called the meeting to order. Ms. Zell reviewed the purpose of the meeting, providing
9 an overview of the agenda.
10

11 2018 Assessment Grid

12 Ms. Zell reviewed the July 1, 2018 Assessment Grid explaining the Board's decision to absorb vaccine
13 inflation and lower the Grid. She stated this is the first year KidsVax® (KV) made a recommendation for
14 the modest 1% reduction in a number of years. The Grid pricing will be in effect on July 1, 2018 for payers
15 based on date of service of vaccine administration on or after July 1, 2018. The Grid change was approved
16 by the Washington Vaccine Board (WVA) on April 5, 2018. Ms. Zell asked Peter Smith to speak to the
17 WVA's current collections and operational reserve and provide support for the Grid change.
18

19 Mr. Smith gave a brief overview of the WVA's financial situation. He stated that there is currently \$32.8
20 million in the bank. WVA's overall financial objective was to create a reserve of three months of vaccine
21 replenishment costs plus the annual costs of flu pre-purchases. The anticipated reserve goal would be
22 between \$22-25 million exclusive of other, anticipated outlays. and we are just over that in cash reserves
23 right now. The investment policy is to invest conservatively about one-half and keep the rest for current
24 cash needs. Therefore, there is a 1% reduction in pricing.
25

26 Ms. Zell asked if there were any questions regarding the 2018 Assessment Grid. Cathy Falanga asked about
27 the discrepancy in pricing between the CDC contract price and the private market with respect to listed flu
28 vaccines. SheAnne Allen, DOH, agreed to check the pricing and make necessary adjustments. Once
29 corrected, the WVA agreed to will re-posted with a note of the changes and re-distribute the Grid via email
30 to Committee members for their review.
31

32 Another question was raised as to when the audit will be completed. Ms. Zell responded that the anticipated
33 date was August and that the financials would be posted after Board approval at the annual meeting in
34 November.
35

36 Ms. Zell noted that another potential change in the 2018 Assessment Grid is the offering of FluMist. The
37 pre-book deadline is May 30 for the upcoming flu season. However, this year the CDC would not have it
38 available for distribution until mid-flu season, meaning any doses obtained during August through perhaps
39 October would need to be purchased off the private market. Ms. Allen stated that the CDC is working with
40 AstraZeneca for delivery date, which presently is unknown. IN order to provide FluMist for the duration
41 fo the flu season for the entire pediatric population, the DOH would need to get utilized WVA funding for
42 initial doses to ensure they receive it in time for August through October. After that, the DOh could utilize
43 the CDC contract. Assuming the DOH proceed with the FluMist order, the vaccine code and assessment
44 amount will be added to the 2018 Assessment Grid.
45

46 Financial Update/Payer Compliance/NDC

47 Ms. Zell reported that KV continues to work on the payer compliance project in an attempt to decrease
48 assessment leakage and ensure that providers and payers are following proper procedures. KV has requested
49 providers to allow KV access to certain key data points on their dosage-based assessment submissions to
50 payers and have contrasted that information with what payers are submitting to the WVA. Norm Roberge

1 stated that some changes need to be made so that the information reported is accurate (i.e., EOBs, correct
2 grids, correct address, etc.). A provider survey is being sent out in July so that KV can measure compliance
3 with the July 1 Grid. Ms. Zell then requested feedback on whether National Drug Codes should be a
4 required field for properly completed assessments. The sense of the Committee was that having Washington
5 payers exempt the WVA from this requirement on medical claims would be preferable. No discussion or
6 questions were raised on any of these topics.

7 8 DOH Updates

- 9 • FluMist: Ms. Allen reviewed the attachments that were included in the packet regarding the
10 possible positions the DOH could take on FluMist. She began by reviewing this year's flu
11 offerings, including all brands. Ms. Allen noted, however, that there is no price for yet. It is
12 estimated at around \$23.80/dose. In an effort to get an idea on whether it should be offered this
13 year, and how many, if any, doses should be ordered, a survey is being sent to providers today with
14 a response deadline of Friday, May 11, 2018. She noted that AstraZeneca has assured us there is a
15 credit for returned/unused doses. Dr. John Dunn reported he had attended a recent National
16 Vaccine Committee meeting and is very interested in hearing the reaction to the survey regarding
17 FluMist. Mr. Dunn requested that WVA get the survey results back before making a decision on
18 FluMist. Julie Liu from AstraZeneca reported that the second week of September is the anticipated
19 ship date for FluMist. There is a 100% return policy for 10-dose packs, as well as single doses. A
20 question was raised regarding the returned vaccine as to whether this is a credit or refund. Ms. Liu
21 noted there would be a credit for unused doses, which would be valid until June 30, 2019. It was
22 noted that AstraZeneca has appointed a medical resource to answer any questions from the
23 Committee. Ms. Liu also noted that WVA's pre-book deadline for FluMist is May 30, 2018. Ms.
24 Zell stated she will email AstraZeneca's contact information to Dr. Marcuse, John Dunn, SheAnne
25 Allen, and Beth Harvey.
- 26 • Best Practices in Vaccine Storage, Handling & Accountability Work: Ms. Allen noted there is a
27 meeting today at 1:00 p.m. regarding this topic and a new policy should be produced by the end of
28 the year.. She invited anyone to join the group if there were interested in contributing.
- 29 • Meningococcal: Ms. Allen reported that Mening is not current on is not the vaccine form, but is
30 available by special request by providers. She stated that due to the strong sense of the WVA
31 Vaccine Committee it would be made available as a normal ordering. Following-up on requested
32 information, she reviewed some additional information on outbreaks and breakdowns regarding
33 how many patients were eligible for the vaccine. This data has been added to the slides. Ms. Allen
34 also stated that the state VAC is revising the current Clinical Guidance document from February
35 2016.

36 37 Other Matters

38 Anne Redman, legal counsel, reminded the Committee that a meeting remains to be scheduled with the
39 DOH and their counsel, Jack Bucknell to discuss FluMist internally. Ms. Zell recommended follow-up
40 correspondence to the Vaccine Committee to discuss the as a result of the provider survey.
41 Ms. Zell also stated the provider and payer pages, as well as final assessment grid with changes will be
42 posted and shared.

43 44 Closing

45 There being no further business, the meeting was adjourned at 12:50 p.m. PST.



What: Combined Vaccine Committee & Operations Committee Meeting
Date & Time: May 3, 2018, 12:00-1:00 p.m. Pacific Time
Call in Number: (267) 930-4000; Conference ID: 103063718#
Location: Teleconference

Notice: Meeting may be recorded for the benefit of the secretary. The WVA intends to delete the recording after the minutes of the meeting are approved.

Approx. Time	Topic/[Anticipated Action]	Presented by:
12:00-12:05 p.m.	1. Introductions & Purpose of Meeting a. Survey of Other Topics	E. Marcuse
12:05-12:10 p.m.	* 2. 2018 Grid Implementation a. Approval of 2018 Assessment Grid	J. Zell
12:10-12:15 p.m.	3. Financial Update	N. Roberge
12:15-12:35 p.m.	4. Operations Update a. Payer Compliance b. NDC	J. Zell
12:35-12:45 p.m.	* 5. DOH Updates a. FluMist b. Restitution Policy & Provider Education	S. Allen
12:45-12:55 p.m.	6. Other Matters from Committee Members	Any
12:55-1:00 p.m.	7. Closing	J. Zell

Washington Vaccine Association Assessment Grid

FOR ALL CLAIMS WITH A DATE OF SERVICE ON OR AFTER JULY 1st, 2018.

Please note that this WVA Assessment Grid, effective July 1, 2018, replaces the grid last updated on July 1, 2017. The grid lists vaccines and their corresponding CPT codes that are part of the dosage-based assessment (DBA) process for providers, health insurance carriers, and third party administrators. There are other childhood vaccines (and corresponding CPT codes) that are not included in the DBA process and, therefore, no assessment is needed. The availability of specific vaccine brands will be determined by the manufacturer and all brands of flu vaccine may not be part of the childhood vaccine program. For a complete listing of all vaccines available through the state Childhood Vaccine Program, please visit the DOH web site: <https://www.doh.wa.gov/ForPublicHealthandHealthcareProviders/PublicHealthSystemResourcesandServices/Immunization/ChildhoodVaccineProgram/StateSuppliedVaccines>.

CPT Code	NDC Code	CPT Code Description	Trade Name(s)	WVA Assessment Amount per dose as of 7/1/2017	CDC Private Sector Cost/Dose	WVA Assessment Amount per dose as of 7/1/2018	Percent change	Notes
90620	58160-0976-20 (10 pack)	Meningococcal recombinant protein and outer membrane vesicle vaccine, Serogroup B, 2 dose schedule, for intramuscular use	Bexsero	\$160.74	\$165.75	\$159.13	-1.0%	Yellow indicates a price increase
	58160-0976-06 (single pack)							
90621	00005-0100-10	Meningococcal recombinant lipoprotein vaccine, Serogroup B, 2 or 3 dose schedule, for intramuscular use	Trumenba	\$115.74	\$133.62	\$114.58	-1.0%	
90633	58160-0825-11 (10 pack, 1 dose vial)	Hepatitis A vaccine, pediatric/adolescent dosage (2-dose schedule), for intramuscular use (Code Price is per dose = 0.5 mL)	Havrix	\$24.98	\$31.95	\$24.73	-1.0%	Yellow indicates a price increase
	58160-0825-52 (10 pack, 1 dose syringe)		Vaqta		\$32.03			
	00006-4831-41							
90636	58160-0815-52	Hepatitis A & Hepatitis B vaccine (HepA-HepB) adult dosage, for intramuscular use (Code Price is per 1 mL).	Twinrix	\$77.35	\$101.00	\$76.58	-1.0%	Age 18 only, no doses expected. Yellow indicates a price increase and corrected NDC Code.
90647	00006-4897-00	Hemophilus influenza b vaccine (Hib), PRP-OMP conjugate (3-dose schedule), for intramuscular use (Code price is per dose = 0.5 mL)	PedvaxHIB	\$17.44	\$26.23	\$17.27	-1.0%	
90648	49281-0545-03	Hemophilus influenza b vaccine (Hib), PRP-T conjugate (4-dose schedule), for intramuscular use (Code price is per dose = 0.5 mL)	Act HIB	\$13.35	\$16.05	\$13.22	-1.0%	
	58160-0818-11		Hiberix		\$10.55		n/a	
90651	00006-4119-03	Human Papilloma Virus (HPV) 9 (nine) valent vaccine, types 6, 11, 16, 18, 31, 33, 45, 52, 58, 3 dose schedule, for intramuscular use (Code Price is per dose = 0.5 mL)	Gardasil 9	\$177.69	\$204.87	\$175.91	-1.0%	
90670	00005-1971-02	Pneumococcal conjugate vaccine, 13 valent, for intramuscular use (Prenar 13 was FDA approved on 2/24/10)	Prenar 13	\$159.57	\$180.05	\$157.97	-1.0%	

CPT Code	NDC Code	CPT Code Description	Trade Name(s)	WVA Assessment Amount per dose as of 7/1/2017	CDC Private Sector Cost/Dose	WVA Assessment Amount per dose as of 7/1/2018	Percent change	Notes
90680	00006-4047-41 (10 pack, 1 dose tube)	Rotavirus vaccine, pentavalent, 3 dose schedule, live, for oral use (Code Price is per dose = 2 mL)	RotaTeq	\$78.17	\$82.89	\$77.39	-1.0%	
	00006-4047-20 (25 pack, 1 dose tube)							
90681	58160-0854-52	Rotavirus vaccine, human, attenuated, 2 dose schedule, live, for oral use (Code Price is per 1 mL = 1 dose)	Rotarix	\$109.72	\$117.45	\$108.62	-1.0%	Yellow indicates a price increase
90696	58160-0812-11 (10 pack, 1 dose vial)	Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated (DTaP-IPV), when administered to children 4 years through 6 years of age, for intramuscular use (Code Price is per one dose = 0.5 mL)	Kinrix	\$48.59	\$50.70	\$48.10	-1.0%	Yellow indicates a price increase
	58160-0812-52 (10 pack, 1 dose syringe)		Quadracel		\$51.67			
	49281-0562-10							
90698	49281-0510-05	Diphtheria, tetanus toxoids, acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated (DTaP - Hib - IPV), for intramuscular use (Code Price is per one dose = 0.5 mL)	Pentacel	\$79.53	\$92.58	\$78.73	-1.0%	
90700	49281-0286-10	Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than seven years, for intramuscular use (Code price is per 0.5 mL dose)	Daptacel	\$23.38	\$30.00	\$23.15	-1.0%	Yellow indicates a price increase
	58160-0810-11 (10 pack, 1 dose vial)		Infanrix		\$24.05			
	58160-0810-52 (10 pack, 1 dose syringe)							
90707	00006-4681-00	Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use (Code Price is per 0.5 mL)	MMRII	\$28.10	\$70.92	\$27.82	-1.0%	
90710	00006-4171-00	Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use (Code Price is per one dose = 0.5 mL)	ProQuad	\$159.66	\$202.41	\$158.06	-1.0%	
90713	49281-0860-10	Poliovirus vaccine, inactivated, (IPV), for subcutaneous or intramuscular use (Code Price is per 0.5 mL dose)	IPOL	\$17.78	\$31.97	\$17.60	-1.0%	
90714	49281-0215-15 (10 pack, 1 dose syringe)	Tetanus and diphtheria toxoids (Td) adsorbed, preservative free, when administered to individuals 7 years or older, for intramuscular use (Code Price is per 0.5 mL)	Tenivac	\$25.60	\$32.89	\$25.34	-1.0%	
	49281-0215-10 (10 pack, 1 dose vial)							
	13533-0131-01				Td Vaccine			

CPT Code	NDC Code	CPT Code Description	Trade Name(s)	WVA Assessment Amount per dose as of 7/1/2017	CDC Private Sector Cost/Dose	WVA Assessment Amount per dose as of 7/1/2018	Percent change	Notes
90715	58160-0842-11 (10 pack, 1 dose vial)	Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use (Code Price is per dose = 0.5 mL)	BOOSTRIX	\$43.41	\$40.05	\$42.98	-1.0%	Yellow indicates a price increase
	58160-0842-52 (10 pack, 1 dose syringe)							
	49281-0400-10 (10 pack, 1 dose vial)		ADACEL		\$44.24			
	49281-0400-15 (10 pack, 1 dose syringe)							
90716	00006-4827-00	Varicella virus vaccine, live, for subcutaneous use (Code Price is per 0.5 mL)	Varivax	\$107.66	\$122.02	\$106.58	-1.0%	
90723	58160-0811-52	Diphtheria, tetanus toxoids, acellular pertussis vaccine, Hepatitis B and poliovirus vaccine, inactivated (DtaP-HepB-IPV), for intramuscular use (Code price is per 0.5 mL)	Pediarix	\$72.72	\$76.95	\$71.99	-1.0%	Yellow indicates a price increase
90732	00006-4943-00	Pneumococcal polysaccharide vaccine, 23-valent, adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use (Code price is per 0.5 mL dose)	Pneumovax 23	\$64.84	\$94.51	\$64.19	-1.0%	
90734	49281-0589-05	Meningococcal conjugate vaccine, serogroups A, C, Y and W-135 (tetraivalent), for intramuscular use (Code Price is per dose = 0.5 mL)	Menactra	\$119.09	\$116.30	\$117.90	-1.0%	Yellow indicates a price increase
	58160-0955-09		Menveo		\$126.95			
90743	00006-4981-00	Hepatitis B vaccine, adolescent dosage (2-dose schedule), for intramuscular use (Code price is per dose) (Recombivax HB 10mcg = one dose)	Recombivax HB	\$17.19	\$23.95	\$17.02	-1.0%	

CPT Code	NDC Code	CPT Code Description	Trade Name(s)	WVA Assessment Amount per dose as of 7/1/2017	CDC Private Sector Cost/Dose	WVA Assessment Amount per dose as of 7/1/2018	Percent change	Notes
90744	58160-0820-52	Hepatitis B vaccine, pediatric/adolescent dosage (3-dose schedule), for intramuscular use (Code price is per dose)	ENGERIX B	\$16.21	\$23.05	\$16.05	-1.0%	

Pediatric Influenza Vaccine Assessments

90685	49281-0518-25 (10 pack - 1 dose syringe)	Influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to children 6 - 35 months of age, for intramuscular use (Code Price is per 0.25 mL dose)	Fluzone Pediatric Preservative Free (PF)	\$23.16	\$19.26	\$23.16	0.0%	Yellow indicates a price increase
90686	19515-0909-52 (10 pack, 1 dose syringe)	Influenza virus vaccine, quadrivalent, split virus, when administered to children 6 months and older	FluLaval	\$16.81	\$16.82	\$16.81	n/a	
90688	49281-0418-10 (10 dose vial)	Influenza virus vaccine, quadrivalent, split virus, when administered to children 6 months and older	Fluzone	\$18.47	\$17.97	\$18.47	0.0%	Yellow indicates a price increase

2018-2019 Prebook Program for FluMist® Quadrivalent



FluMist® Quadrivalent Influenza Vaccine Live, Intranasal

Prebook FluMist Quadrivalent by May 31, 2018, to qualify for enhanced discounts and enhanced returns. See program details for more information; some restrictions apply.

More information is available at McKesson.com or by calling McKesson Medical at 1-877-625-4358.

2018-2019 Pricing and Returns Information for FluMist® Quadrivalent

This season's market offering includes two valuable extra benefits for ordering by **May 31, 2018**:

- An **additional 2%** discount over the base discount
- An **additional 50%** returns provision over the base provision

MARKET OFFERING		DISCOUNT % OFF LIST PRICE*	RETURNS PROVISION
Base Benefit†		15%	50%
Additional Benefit‡	+	2%	50%
Total Benefit		= 17%	100%

*List price is \$22.95 per dose. Excise tax of \$0.75 not included. Additional Distributor fees may apply.

†Base Benefit applies to all prebooks and orders June 1, 2018 to June 30, 2019.

‡Additional Benefit is contingent upon Customers prebooking prior to May 31, 2018, and will also apply to all re-orders of product June 1, 2018 to June 30, 2019.

Prebook Order Here	Item #	MFG	Description	PKG QTY Requested	Doses/ PKG	Confirm Total Doses	Discounted Price/PKG	Final Price/PKG Includes \$7.50 Federal Excise Tax
	AZSPRY18	AstraZeneca	FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) Supplied in a package of 10 pre-filled, single-use sprayers. Product must be kept refrigerated (2°-8°C/35°-46°F) at all times prior to use.		10		\$190.49 [§]	\$197.99 [§]

[§]Exclusive of Federal Excise Tax of \$0.75 per dose

Price reflects an additional discount of 2% for orders placed by May 31, 2018 and will increase by 2% for orders placed after June 1, 2018.

Please provide the following information:

Office Contact Name _____

Practice Name _____

Ship to Address _____

City _____ State _____ ZIP _____

Phone _____ Fax _____

Email _____

Signature (required) _____

Date _____ PO _____

McKesson Account Number _____

Check to set up a new account — If you do not have a current McKesson Medical Account Number, please check here and we will send you everything you need.

Questions?

Call 1-877-625-4358

MCKESSON

<https://mms.mckesson.com>

Prices are subject to change without prior notification. Neither McKesson Medical-Surgical nor any of its affiliates ("McKesson") guarantee any specific delivery date or quantity. McKesson will not be held liable for any delays or product shortages.

You agree that this is a binding order which may only be canceled by delivering McKesson written notice of cancellation prior to July 13, 2018. By placing this order, you agree to purchase the designated product upon delivery. After July 13, 2018, you may cancel only the quantity of product that McKesson fails to deliver by November 16, 2018. The sale price indicated includes freight unless separately identified on the invoice. McKesson's standard terms of sales are incorporated by reference and apply to this order for product.

IN NO EVENT SHALL MCKESSON BE LIABLE FOR INCIDENTAL, SPECIAL, OR CONSEQUENTIAL DAMAGES, WHETHER BASED ON BREACH OF CONTRACT, WARRANTY, TORT, PRODUCT LIABILITY, OR OTHERWISE, (INCLUDING LOST PROFITS) FROM ANY CAUSE, INCLUDING WITHOUT LIMITATION, DAMAGES RESULTING FROM ANY UNAVAILABILITY OF, DEFECT IN, OR MISSHIPMENT OF PRODUCTS OR THE PROVISION OF SERVICES, AND WHETHER OR NOT MCKESSON HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE.

Fax this back to McKesson Medical at 1-855-888-8358 or e-mail to Fluconnection@mckesson.com

FluMist Questionnaire for Providers:

ACTION NEEDED: Survey response requested to guide 2018-2019 flu season vaccine ordering

The Advisory Committee on Immunization Practices (ACIP) recently added FluMist to the list of recommended influenza vaccines for the 2018-2019 flu season. This addition came after Washington State had submitted our 2018-2019 flu vaccine pre-book to the Centers for Disease Control and Prevention (CDC). We need your input to decide whether to purchase FluMist for next flu season.

Background:

FluMist is a live attenuated influenza vaccine, and is the only non-injection flu vaccine option available. In June, 2016, ACIP stopped recommending the use of FluMist due to concerns of decreased effectiveness against influenza A (H1N1) strain and the vaccine was removed from Washington State's order list. The manufacturer reformulated the vaccine changing the H1N1 component.

In early February every year, Washington must pre-book the presentations and number of doses of flu vaccine that they would like to purchase off the CDC contract for the upcoming flu season. This pre-book is a final commitment and we can't change or cancel any part of the order.

In late February, 2018, after Washington submitted the pre-book order, the ACIP voted to include FluMist in the list of recommended influenza vaccines for the 2018-19 flu season. The state must now decide whether and how FluMist should be purchased and offered for the 2018-19 flu season.

Action Needed:

In preparation for the 2018-2019 flu season, we are reaching out to providers to gather data on FluMist interest, demand and logistics.

A few things to consider, this is a live attenuated influenza vaccine that is a nasal spray. Due to it being a live attenuated vaccine it has a shorter expiration date, generally 10 to 12 weeks. This vaccine is licensed for 2 -49 years of age.

Please respond to this short four questions survey by XX.

1. Is your clinic interested in ordering and administering the FluMist vaccine next flu season?

YES NO

2. How many doses would you anticipate using for children aged 2 years thru 18 years of age?

3. Would your clinic still be interested in using FluMist if only a small supply was available?

YES NO

4. Would receiving FluMist later than the other presentations offered change your mind about ordering FluMist?

YES

NO



WVA VACCINE UPDATE

SheAnne Allen

May 3, 2018

Vaccine Update

- LAIV
- Restitution
- MenB



LAIV things to consider

- ✓ Cost
 - ✓ 2016 CDC Price \$18.88
 - ✓ 2016 Private Price \$23.70
 - ✓ 2018 estimated Private Price \$19.80
- ✓ Provider/VAC feedback
- ✓ Feedback from survey to determine # of doses
 - ✓ Include calls to get more feedback

LAIIV things to consider (2)

- ✓ 100% return if pre-book before May 31, 2018
- ✓ 10-12 week expiration
- ✓ No confirmed delivery date
- ✓ CDC approval
- ✓ CDC Fall Pre-book

LAIV Survey

1. Is your clinic interested in ordering and administering the FluMist vaccine next flu season?

YES

NO

2. How many doses would you anticipate using for children aged 2 years thru 18 years of age?

3. Would your clinic still be interested in using FluMist if only a small supply was available?

YES

NO


4. Would receiving FluMist later than the other presentations offered change your mind about ordering FluMist?

YES

NO

Best Practices in Vaccine Storage, Handling, and Accountability Work

- Follow up discussions and consultation with CDC will be taking place
- Call 1 PM today!



Meningococcal


- 11 cases in 2017
- Obtain serogroups on 10 of the 11 cases:
 - Serogroup C 6 age range 3 – 77 years
 - Serogroup B 3 2 infants under 1 year of age, and a 73 year old
 - Serogroup Z 1 Not vaccine preventable
- Recent WA trend: During the past decade, an average of 22 cases (range 10-29) have been reported annually, with as many as five deaths in a year.



Number of Meningococcal Disease Cases by Serogroup, WA 2007-2016


Year	Total	Not Tested*	Isolate available	B	C	Y	W135	Other	% Vaccine (A/C/Y/W) serogroup	% B
2007	28	1	27	13	4	10	0	0	52%	48%
2008	31	3	28	11	5	9	2	1	57%	39%
2009	25	2	23	13	2	8	0	0	43%	57%
2010	29	2	27	7	7	12	1	0	74%	26%
2011	22	0	22	12	2	7	1	0	45%	55%
2012	24	0	24	9	4	8	0	3	50%	40%
2013	20	3	17	9	2	3	2	1	41%	53%
2014	17	0	17	6	5	4	1	1	59%	35%
2015	10	0	10	3	4	1	2	0	70%	30%
2016	13	1	12	3	6	1	1	1	67%	25%
Total	219	12	207	86	41	63	10	7	55%	42%

MenB Doses Ordered Nov 2015- March 2018



MCV4 VS MenB Doses Ordered

Nov 2015- March 2018



MenB Follow-up

- Adding to form during next Vaccine Selection (October)
- VAC will revise the current VAC Clinical Guidance document from February 2016





WVA VACCINE COMMITTEE MEMBERS

Voting members

Chair: Ed Marcuse, MD (physician member, appointed by Secretary)
Members: John Dunn, MD (Kaiser Permanente)
Michele Roberts (Secretary's representative)

Non-Voting Members

SheAnne Allen, Ex-Officio (without vote)
Jeff Gombosky (Manufacturer's representative to Committee under HB 2551,
sec. 5(1) without vote)

Volunteer Member Mary Kay O'Neill, MD (public member)

Vaccine Committee Consultants

Critical members are from local health, Pharma, and family practice. The Committee will from time to time bring in others with different expertise as needed.

Chad Murphy, PharmD
Jeffrey Duchin, MD
Lisa Johnson, MD
Rachel Wood, MD